Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) this week announced positive, prospective results from an ongoing Covid-19 Phase 2/3 outpatient trial. The results show that Regeneron's investigational antibody cocktail, REGN-COV2, met primary and key secondary endpoints, significantly reducing viral load and patient medical visits (which include hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits). You can read the full report here.

Sarasota Memorial Hospital is currently enrolling patients in Regeneron's REGN-Cov-2 trial for preventing Covid-19 in healthy adults, as well as its study of the REGN-CoV-2 antibody cocktail for treating COVID-19 in hospitalized and non-hospitalized adults. For more information, click here.